Anpario (ANP) Q4 2024 TU earnings summary

Trading performance

• Achieved stronger than expected operating performance in H2 2024, with year-end sales exceeding forecasts.

• Revenue for FY 2024 expected to be approximately £37.5m, up from £31.0m in 2023.

• Adjusted EBITDA anticipated to surpass current market expectations due to operational gearing and favorable FX movements.

• Bio-Vet Inc. contributed a strong final quarter, driven by demand for dairy cow health products amid avian influenza.

• Middle East and Africa segment delivered outstanding sales performance.

Financial position and outlook

• Year-end cash balances remain robust at £10.5m after the Bio-Vet Inc. acquisition.

• Acquisition of Bio-Vet Inc. and related assets completed for US$6.3m on a debt-free basis.

• Strong balance sheet supports investment in innovation, global expansion, and further acquisitions.

• Confident in ability to capitalize on growth opportunities and deliver long-term stakeholder value.

• FY 2024 final results expected to be published around 26 March 2025.